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 ABSTRACT
Calciphylaxis is a rare and devastating obliterative vasculopathy, leading to ischemia and subcutane-
ous necrosis. In most cases it affects patients with renal disease and is associated with high morbidity 
and mortality. We present two case reports followed recently in our department, and a literature review 
on this topic. Case one refers to an 80 -year -old Caucasian woman with chronic kidney disease stage 5 
and primary hyperparathyroidism with secondary brown tumour and calciphylaxis. Case two refers to a 
59 -year -old Caucasian woman admitted with severe nephrotic syndrome associated with amyloidosis, 
that developed a catastrophic picture of calciphylaxis, ending in the patient’s death. There is a critical 
need to understand the pathogenesis of calciphylaxis. Its comprehension is the only way to improve 
the survival of these patients, and may help to elucidate the pathophysiology of vascular calcification 
in general. Educating physicians in the prevention and early detection of calciphylaxis is crucial. Only 
by increasing the knowledge about risk factors, pathophysiology, response to treatment and outcome, 
will we be able to improve prophylaxis and therapy of patients with calciphylaxis, decreasing the high 
mortality of this entity.
Key -words: calciphylaxis; chronic kidney disease; primary hyperparathyroidism.
 RESUMO
A calcifilaxia é uma vasculopatia obliterativa devastadora e rara que leva a isquémia e necrose 
subcutânea. Afeta principalmente doentes com doença renal crónica sendo responsável por elevada 
morbilidade e mortalidade. No presente trabalho apresentamos dois casos clínicos recentemente acom-
panhados no nosso serviço, fazendo uma revisão bibliográfica sobre este tópico. O primeiro caso 
refere -se a uma mulher de 80 anos com doença renal crónica estadio 5, calcifilaxia e tumor de brown 
associados a hiperparatiroidismo primário. O segundo caso refere -se a uma mulher de 59 anos admitida 
por síndrome nefrótica associada a amiloidose com um quadro de calcifilaxia súbito e catastrófico que 
terminou com o óbito da paciente. A compreensão da patogénese da calcifilaxia poderá melhorar a 
sobrevivência destes doentes e, eventualmente, ajudar a elucidar a fisiopatologia da calcificação 
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vascular em geral. Informar os médicos para a prevenção e deteção precoce da calcifilaxia é crucial. 
Apenas aumentando o conhecimento dos fatores de risco, fisiopatologia, resposta ao tratamento e 
prognóstico seremos capazes de otimizar a profilaxia bem como a terapia de doentes com calcifilaxia 
e diminuir a elevada mortalidade associada a esta entidade.
Palavras chave: calcifilaxia; doença renal crónica; hiperparatiroidismo primário.
 INTRODUCTION
Calciphylaxis is a rare and serious disorder char-
acterized by medial calcification of the arterioles, 
leading to ischaemia and subcutaneous necrosis. It 
most often affects patients with end -stage renal dis-
ease (ESRD), on chronic dialysis or following renal 
transplantation, and leads to high morbidity and 
mortality.
The term calciphylaxis emerged, in 1961, by Selye 
et al. during early animal experiments1, as a sys-
temic hypersensitivity reaction similar to allergic 
reaction (anaphylaxis), and the term was adapted 
to human medicine afterwards2. Despite the resem-
blance with the animal, the skin lesion described 
by Selye et al., characterized by tissue calcification, 
in the human cases, vascular calcification predomi-
nates, and the term calcific uremic arteriolopathy 
(CUA) has been proposed as a more suitable 
name3. As this clinical disorder has been reported 
in patients without uraemia, CUA can also be mis-
leading, and the term calciphylaxis is still widely 
applied.
The incidence and prevalence of calciphylaxis 
remains to be determined. It has been described 
that can reach up to 5% of dialysis -dependent 
patients4, but recent data from Germany5 and 
Japan6 suggested incidence of 1%. Calciphylaxis 
is still overlooked by clinicians and improved clini-
cal awareness, as well different environmental and 
ictogenic factors, may increase its incidence in the 
future.
Although the advances made in the comprehen-
sion of the disease, the heterogeneity of patients 
and disease manifestations, allied to its rarity, 
have been an obstacle to any large -scale random-
ized controlled trial, concerning understanding and 
treatment of this disease. To overcome the problem 
Hayashi et al. had conducted a systematic nation-
wide survey collecting data from all cases of cal-
ciphylaxis treated in the majority of Japanese 
dialysis centers. Afterwards the authors performed 
a case–control study to identify the characteristics 
of calciphylaxis in the Japanese dialysis popula-
tion6. An Internet -based registry (http://www.cal-
ciphylaxie.de) was also started in Germany with 
about 160 cases prospectively collected since late 
2006.
In this paper we present two case reports recently 
diagnosed in our department, and we will review 
the literature on this topic.
 CASE 1
An 80 -year -old woman was admitted for dialysis 
initiation. Relevant medical history includes chronic 
kidney disease (CKD) stage 5 due to secondary 
glomerulosclerosis (right nephrectomy for lithiasis 
at 54 years old) and tubulointerstitial nephritis. 
She was medicated with enalapril 20 mg/day and 
darbepoetin 20 μg/week, with no other associated 
drugs (like vitamin D analogues or calcium -based 
phosphate binders). At admission, she presented 
painful, indurated subcutaneous nodules in the 
lower limbs, and a deformation of the left clavicle, 
that the patient related with trauma 3 months 
earlier. Meanwhile, diffuse cranial heterogeneity 
with several infra -centrimetric lesions was found 
in a cranial CT performed to study syncopal epi-
sodes presented during haemodialysis. Of the fol-
lowing study we point: normal immunoelectropho-
resis and serum free light chain; Calcium (Ca): 9.2 
mg/dl; Phosphate (Pi): 4.5 mg/dl; intact parathyroid 
hormone (iPTH) > 2500 pg/ml. A parathyroid 
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ultrasound revealed nodules of solid hypoechoic 
characteristics (20×9 mm at right) and the scintig-
raphy, set with Sestamibi, revealed hyperfunction-
ing parathyroid tissue. At this time, an angio -CT 
was performed to the bone deformation, which 
revealed a bone lesion very likely to represent a 
Brown tumour. As the nodules in the lower limbs 
became more painful, with marmoreated skin and 
a dark ulcer (Fig. 1), a biopsy specimen of the skin 
was obtained and revealed calciphylaxis (Fig. 2). 
As a final diagnosis, primary hyperparathyroidism 
with secondary brown tumour and calciphylaxis 
were admitted. The lesions of calciphylaxis disap-
peared as haemodialysis, carbonate sevelamer and 
cinacalcet were initiated, with no further treatment 
required. The iPTH regressed to 1064 pg/ml and 
the patient is waiting for parathyroidectomy.
 CASE 2
A 59 -year -old Caucasian woman with past medi-
cal history relevant for uterine cancer treated with 
radiotherapy, complicated by radiation cystitis, 
radic colitis with colostomy. She developed severe 
nephrotic syndrome associated with amyloidosis 
in renal and skin biopsies, not able to be charac-
terized by immunohistochemistry, was admitted 
due to acute on chronic renal failure [plasmatic 
urea (Pu) 115mg/dl, plasmatic creatinine (Pcr) 2.6 
mg/dl] secondary to dehydration, Escherichia Coli 
urinary infection and bilateral hydronephrosis. 
Renal function improved after initiation of antibiot-
ics and ureter catheterization. At the 26th day, 
following a nosocomial infection, a further deterio-
ration of the renal function was observed. Labora-
tory findings revealed Pu: 138 mg/dl; Pcr 4.1mg/
dl; Pi 14.9mg/dl; serum calcium 6.6 mg/dl; iPTH 
265 pg/dl; Albumin: 1.2 mg/dl. A livedo reticularis 
in the lower limbs (thighs and legs) changed rapidly 
to extensive necrosis plaques. A biopsy specimen 
of the skin confirmed the suspicion of calciphylaxis. 
The patient started an intensive dialysis programme 
along with sevelamer and local wound care with 
surgical debridement, which improved her condi-
tion. One month later, a general clinical worsening 
was observed associated to bleeding dyscrasia 
(INR: 14.4; apTT: 82.1 s), most likely associated 
to factor X deficit, resultant of its connection to 
amyloid fibrils. The patient continued to deteriorate 
and died on the 75th day.
Figure 2
Medial calcification and intimal proliferation in small arteries.
 
Figure 1
Cutaneous lesions of calciphylaxis
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  HOW TO RECOGNIZE AND 
DIAGNOSE CALCIPHYLAXIS
Confirmation of calciphylaxis is a crucial issue as 
late intervention is associated with unjustified thera-
peutic measures and poorer prognosis.
Diagnosis requires a high degree of clinical sus-
picion and is made clinically based in a triad:
a) Painful skin lesions, often refractory to standard 
analgesics4.
b) Cutaneous lesions with characteristic progres-
sive appearance. Initial lesions appear as red 
sub -cutaneous nodules or violaceous plaques, 
often in a livedo reticularis pattern. Lesions 
may increase in size and form ecchymosis or 
single indurated plaque formation, finally end-
ing in characteristic black skin, deeply ulcerated 
scars and necrosis7.
c) Medial calcification and intimal proliferation in 
small arteries are characteristic histological fea-
tures4, along with thrombotic vaso -occlusion, 
without vasculitic pattern.
Tissue biopsy remains the gold standard for diag-
nosis, but should not be routinely performed because 
of the risk of sampling error, inoculating or spreading 
infection and tissue trauma leading to ulcer 
progression7 -9.
The progressive lesions may reflect two processes 
of disease: initially calcific arteriolopathy, and lately 
ischaemic necrosis, related to reduced perfusion or 
vascular thrombosis10,11. This suggests that these 
skin lesions may be the equivalent of the lesions 
found in myocardial infarction12. Lesions frequently 
occur over areas with high adipose tissue content as 
it has less blood supply than other tissues8, 9. These 
lesions can be classified as distal (extremities), often 
in slim and malnourished patients, or proximal (trunk, 
thighs and/or buttocks), often in obese patients. 
Proximal pattern is more associated with deep ulcer-
ations and fat tissue necrosis8. The distal pattern 
appears to have a better survival rate13.
Many dermatologic disorders resemble the super-
ficial lesions of calciphylaxis, but a careful patient 
history and histopathology can distinguish them7. 
Clotting disorders, such as protein C, protein S and 
antithrombin III deficiency and autoimmune dis-
eases, may present with similar skin lesions and 
should be excluded4. A detailed list of differential 
diagnoses, as peripheral vascular disease, vascu-
litis, atheroembolism, warfarin therapy, has been 
published10.
Currently, imaging plays a limited role in diag-
nosing calciphylaxis. Mammography has been pro-
posed but can be a painful procedure14, but bone 
scintigraphy with Tc99m methylene diphosphate 
has shown promise as a diagnostic tool for calci-
phylaxis in the detection of subcutaneous calcium 
deposits9,15.
  SEARCHING THE RECIPE 
FOR CALCIPHYLAXIS
The pathophysiology of calciphylaxis is complex 
and poorly understood. Many factors have been 
appointed as potential risk factors for the develop-
ment of calciphylaxis but they faced significant limi-
tations in the distinction between causality and pure 
association.
The most mentioned risk factor is CKD, particularly 
end -stage renal disease, metabolic abnormalities, 
and therapies associated as chronic kidney disease–
mineral bone disorders5,9,16,17, (CKD -MBD) definition 
according to the KDIGO nomenclature18.
Hyperphosphataemia, hypercalcaemia and hyper-
parathyroidism play a well documented pathologic 
role in vascular calcification but its effect on the 
genesis of calciphylaxis is not as well estab-
lished4,8,13,17. The vast majority of dialysis patients 
with comparable degrees of CKD -MBD never develop 
calciphylaxis and often calciphylaxis patients do not 
show uncontrolled values of mineral metabolism at 
the time of diagnosis. The discrepancy found in bio-
chemical parameters may be partly explained by 
methodological variations in assays and by different 
intervals between the exposition to calcification pro-
moting factors and clinical manifestations of calci-
phylaxis19. For the development of calcyphilaxis, the 
total calcium load and hyperphosphataemia period 
seems much more relevant than the isolated 
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measurement of high calcium or high phosphate 
serum levels.
In recent reports, warfarin therapy8, low serum 
albumin level and high plasma glucose level were 
significantly associated with calciphylaxis6,8.
Albumin level has already been related to the risk 
of thrombotic complications in nephrotic syndrome 
and as a marker for calcification. Even so, its role 
is confounded as it is regulated as negative acute-
-phase reactant, and can reflect malnutrition and 
increased dialysis -related mortality13,14,20.
Other risk factors frequently mentioned include 
female gender9,16, probably related to increased fat 
mass, diabetes4,5,8,9,16, obesity14,16 and hypercoagu-
lable states, resulting from protein C and S defi-
ciency17,21,22, or antiphospholipid syndrome23. The 
pathologic changes of calciphylaxis promote by them-
selves thrombus formation that can be exacerbating 
by hypercoagulable states16.
A systematic review of conditions associated with 
non -uraemic calciphylaxis has been published19. Most 
cases are due to primary hyperparathyroidism, malig-
nancies24,25, connective tissue diseases26,27 and 
alcoholic liver disease16,19,22. Hyperparathyroidism is 
the most commonly reported condition but still has 
not been consistently recognized as an independent 
risk factor for the development of calciphylaxis4,19.
Research in cardiovascular and bone diseases has 
identified a link between bone and vascular calcifica-
tion. Factors such as receptor activator of nuclear 
factor -kB [RANK], RANK ligand and osteoprotegerin 
(OPG), which plays important roles in mineral deposi-
tion and bone resorption, also seems to regulate 
extra -skeletal mineralization. Derangement of this 
system has been tied to certain bone diseases and 
may underlie the pathogenesis of calciphylaxis12,16,28. 
Also, polymorphisms or deficiencies of OPG result 
in increased arterial calcification29.
Some of the factors that can predispose to calci-
phylaxis (iPTH, corticosteroids, aluminum, liver dis-
ease, autoimmune states and various forms of inflam-
mation) are known to increase the expression of 
RANK ligand, decreasing the expression of OPG, thus 
activating RANK and prompting calciphylaxis16,19. 
Furthermore, histological examinations suggest that 
calcification is associated with increased expression 
of osteopontin by smooth muscle cells20.
In the first patient, we find that primary hyperpara-
thyroidism, supported by the osteolitic lesions and 
Brown tumour, was the sensitizing factor (despite the 
normal calcium and phosphorus serum levels at pre-
sentation) and that renal failure was the trigger to 
calciphylaxis. For the development of calciphylaxis, the 
total calcium load and hyperphosphataemia period 
seems much more relevant than the isolated measure-
ment of high calcium or high phosphate serum levels. 
In the second patient we can assume that factor X 
deficit, associated to amyloidosis, CKD and severe 
hypoalbuminaemia (Alb: 1.2 g/dl) were the predispos-
ing factors. While acute exacerbation of chronic kidney 
failure, associated with acute hyperphosphataemia (Pi: 
14.9 mg/dl), was the main trigger to calciphylaxis. In 
both cases CKD, as well as CKD -MBD, were present.
  ROLE OF CALCIFICATION 
INHIBITORS
Deficiencies in vascular calcification inhibitors, 
such as fetuin -A and matrix Gla protein (MGP), have 
been postulated to play a key role in calciphylax-
is12,28,30. Fetuin -A levels are reduced in patients with 
renal failure and in patients with inflammation31. 
Serum levels of both calcification inhibitors are espe-
cially low in patients with calciphylaxis, and the 
ability to inhibit basic calcium phosphate precipita-
tion is much lower than in healthy controls30,31. 
Warfarin suppresses MGP function, which may explain 
the increased risk of calciphylaxis associated with 
this therapy4 -6,32.
The fact that only a small minority of patients 
develop calciphylaxis makes a multifactorial patho-
genesis most likely. Selye’s induced calcification in 
a two -step model, suggesting a sequential course 
of pathophysiological events, which closely approxi-
mates the description of vascular calcification that 
might occur in human calciphylaxis1. In a modern 
definition of Selye’s calciphylaxis we may admit that 
probably the disease is a result of multiple factors 
that can sensitize and predispose patients to calci-
phylaxis development. These factors directly or indi-
rectly activate NFkB, resulting in bone pathology and 
vascular calcification12.
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 HOW TO TREAT CALCIPHYLAXIS?
There is no evidence -based medicine treatment 
option available for patients with calciphylaxis and 
a standard protocol has not been formally developed, 
due to late diagnosis and dismal prognosis. The 
heterogeneity of treatment amplifies the difficulties 
in establishing a correct evaluation of the success 
of different therapeutic approaches. Moreover, with 
the advances in our understanding new treatment 
options have emerged.
Calciphylaxis involves a multidisciplinary approach. 
Dermatologists, surgeons and nephrologists need to 
work hand -in -hand.
The initial management of the disease consists of 
supportive management, such as diligent wound care. 
Patients undergoing wound debridement appear to 
have improved survival16. Aggressive infection therapy 
is needed, as sepsis is the chief cause of death. Pain 
control is of great importance and nutritional support 
of patients affected by malnutrition is vital.
Reduce or, if possible, discontinue medications 
that have been implied in calchiphylaxis8. Probably 
the role of the iatrogenic intervention has been fun-
damental in the final step of the disease leading 
sensitized patients to calciphylaxis33. Indeed, calci-
phylaxis does not appear to be part of natural pro-
gressive CKD (as renal anaemia), since most patients 
do not develop it. Surprisingly, most patients with 
calciphylaxis benefited of medical surveillance and, 
therefore, the development of calciphylaxis might 
actually have iatrogenic components8,33.
In fact, various pharmacologic or biological agents 
have been implicated in causing calciphylaxis, the 
most well -known being high -dose vitamin D and its 
analogues9,16, calcium supplementation9, warfarin16, 
chemotherapy agents21, iron dextran9,38 and eryth-
ropoietin13. Steroids are controversial and have been 
implicated as a cause16, as well as a therapeutic 
option9,16,17,19.
Control of metabolic disturbances (hyperparathy-
roidism, hypercalcaemia, hyperphosphataemia) 
makes good clinical sense, although better outcomes 
have not been demonstrated16,34. Calcium loads can 
be decreased by reducing dialysate calcium to levels 
of ≤ 1.25 mmol/L and administering calcium -free 
phosphate binders. It has been showed that reducing 
the amount of calcium salts administered can drop 
the incidence of calciphylaxis33. Intensifying dialysis 
sessions in affected patients to increase calcium and 
phosphate removal8 or changing from peritoneal to 
haemodialysis may help33.
The most significant progress in treatment has been 
the use of sodium thiosulphate(STS)35,36. STS seques-
ters calcium ions to form highly soluble calcium thio-
sulfate complexes and can prevent calcium phosphate 
precipitation36 -38. It is also an effective antioxidant 
and may, thus, limit tissue damage39. The benefits of 
STS in calciphylaxis patients include rapid pain relief 
and successful wound healing within weeks to months 
of initiating therapy37, 39. Side -effects, as metabolic 
acidosis, are low. One interesting new development 
may be the topical use of a 25% STS ointment40.
Hyperbaric oxygen therapy (HBO) has been shown 
to improve wound healing counteracting tissue 
hypoxia by supplying high concentrations of oxygen; 
however, positive effects were largely limited to 
patients with distal forms of calciphylaxis4,36.
Parathyroidectomy can improve calciphylaxis, but 
it should be limited to cases of refractory hyperpara-
thyroidism with calcium receptor antagonists3,41. 
Cinacalcet has the unique ability to lower parathyroid 
hormone, calcium, and phosphate levels7,42. Applica-
tion of bisphosphonates42 and vitamin K supple-
mentation is controversial32.
All treatment alternatives available should be used 
for the treatment of calciphylaxis to promote syner-
gistical actions that maximize the potential for wound 
healing and subsequent patient recovery7.
As the pathogenesis of calciphylaxis is being better 
understood, targeted molecular therapies may 
become the way for therapeutic prevention.
 PROGNOSIS
Calciphylaxis is a severe and life -threatening con-
dition, with a mortality rate ranging from 46% to 
80%16. It has been noted that the highest mortality 
is associated with secondary infection of the cutane-
ous lesions, leading to sepsis7.
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Factors associated with poorer overall prognosis 
include skin lesions involving the trunk, ulceration 
of skin lesions, female gender, increased weight, and 
the need for vascular surgical intervention9,17,43.
 CONCLUSION
Calciphylaxis is a rare, life -threatening complication 
of ESRD, although not exclusive to these patients.
There is a critical need to understand pathogenesis 
of calciphylaxis. Its comprehension is the only way 
to improve the survival of these patients and it may 
help to elucidate the pathophysiology of vascular 
calcification in general.
As seen in our case reports, it is fundamental to 
recognize the risk factors and keep great awareness 
to make the diagnosis as soon as possible in order 
to start the treatment and try to prevent the drastic 
consequences of the disease.
As we further expand our understanding of the com-
plexity of vascular calcification, new therapeutic agents 
with the potential for preventing vascular calcification 
will arise. The effect of the introduction of non calcium-
-containing phosphate binders on the incidence and 
prevalence of calciphylaxis remains to be seen.
The participation in national and international 
registers of calchiphylaxis is an excellent tool to get 
an idea of the epidemiology of the disease5.
Educating physicians to prevention and detection 
of calciphylaxis is crucial. Only by increasing the 
knowledge of risk factors, pathophysiology, response 
to treatment and outcome, will we be able to improve 
prophylaxis as well as the therapy of patients, and 
to decrease the high mortality of this entity.
Conflict of interest statement:None declared.
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